JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2016, Vol. 54 ›› Issue (4): 68-73.doi: 10.6040/j.issn.1671-7554.0.2015.1011

Previous Articles     Next Articles

Dual-Phase 18F-FDG PET/CT in the diagnosis of benign and malignant pancreatic lesions

SUN Xuyi, HAN Jiankui   

  1. Department of Nuclear Medicine, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Received:2015-10-26 Online:2016-04-10 Published:2016-04-10

Abstract: Objective To evaluate the diagnostic value of dual-phase PET/CT in the differential diagnosis of benign and malignant pancreatic lesions. Methods The 18F-FDG PET/CT conventional imaging was performed on 81 cases of malignant pancreatic lesions and 41 cases of benign pancreatic lesions. Of them, 46 of the malignant cases and 22 of the benign cases received delayed imaging. The best cut-off point value of maximum standardized uptake value for early phase(SUVearly)and retention index(RI)were explored. Results Among the 122 cases undergoing 18F-FDG PET / CT examination, SUVearly of malignant cases(5.46±3.51)was significantly higher than that of benign cases(1.89±1.28)(P<0.05), while SUVdelay of malignant cases(5.87±3.79)was higher than that of benign cases(2.64±1.94)(P<0.05). Among the 68 cases undergoing the dual-phase PET/CT, there was no significant difference between SUVearly(2.33±1.25)and SUVdelay(2.64±1.94)in benign cases(P>0.05), while in malignant cases, SUVdelay(5.87±3.79)was significantly higher than SUVearly(4.52±2.98)(P<0.05). According to the ROC curve, when the best cut-off value of SUVearly was 2.75, the sensitivity, specificity and accuracy were 82.72%, 80.49% and 81.97% respectively. When RI%=12.04% was set as the boundary value, the sensitivity, specificity and accuracy were 82.61%, 72.72% and 79.41%, respectively. When SUVearly=2.75 and RI%=12.04% were jointly considered, the 山 东 大 学 学 报 (医 学 版)54卷4期 -孙旭怡,等.18F-FDG PET/CT双时相显像对胰腺良恶性病变鉴别的诊断价值 \=-sensitivity, specificity and accuracy were 93.48%, 59.10% and 82.35%, respectively. Conclusion 18F-FDG dual-phase PET/CT has a good diagnostic value in differentiating benign pancreatic lesions from malignant ones.

Key words: Pancreatic cancer, 18F-FDG, Dual-Phase, Standardized uptake value, PET/CT

CLC Number: 

  • R574
[1] Wang XL, Yang F, Jin C, et al. Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer[J]. World J Gastroenterol, 2014, 20(42): 15580-15589.
[2] Bipat S, Phoa SS, van Delden OM, et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis[J]. J Comput Assist Tomogr, 2005, 29(4): 438-445.
[3] Tang S, Huang G, Liu J, et al. Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: A meta-analysis[J]. European Journal of Radiology, 2011, 78(1): 142-150.
[4] Lodge MA, Lucas JD, Marsden PK, et al. A PET study of 18FDG uptake in soft tissue masses[J]. Eur J Nucl Med, 1999, 26(1): 22-30.
[5] Kawada N, Uehara H, Hosoki T, et al. Usefulness of Dual-Phase 18F-FDG PET/CT for Diagnosing Small Pancreatic Tumors[J]. Pancreas, 2015, 44(4): 655-659.
[6] Nakamoto Y, Higashi T, Sakahara H, et al. Delayed(18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas[J]. Cancer, 2000, 89(12): 2547-2554.
[7] Rijkers AP, Valkema BR, Duivenvoorden HJ, et al. Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: A meta-analysis[J]. Eur J Surg Oncol, 2014, 40(7): 794-804.
[8] Nishiyama Y, Yamamoto Y, Monden T, et al. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour[J]. Nucl Med Commun, 2005, 26(10): 895-901.
[9] Yoshioka M, Uchinami H, Watanabe G, et al. F-18 fluorodeoxyglucose positron emission tomography for differential diagnosis of pancreatic tumors[J]. Springerplus, 2015, 4: 154.
[10] Friess H, Langhans J, Ebert M, et al. Diagnosis of pancreatic cancer by 2[18F] -fluoro-2-deoxy-D-glucose positron emission tomograpgy[J]. Gut, 1995, 36(5): 771-777.
[11] Delbeke D, Martin WH. PET and PET/CT for pancreatic malignancies[J]. Surg Oncol Clin N Am, 2010, 19(2): 235-254.
[12] Ozaki Y, Oguchi K, Hamano H, et al. Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography[J]. Gastroenterol, 2008, 43(2): 144-151.
[13] Kamisawa T, Takum K, Anjiki H, et al. FDG-PET/CT findings of autoimmune pancreatitis[J]. Hepatogastroenterology, 2010, 57(99-100): 447-450.
[14] Shigekawa M, Yamao K, Sawaki A, et a1. Is 18F-fluorodeoxyglueose positron emission tomography meaningful for estimating the efficacy of corticosteroid therapy in patients with autoimmune pancreatitis?[J]. J Hepatobiliary Pancreat Sci, 2010, 17(3): 269-274.
[15] Zimny M, Bares R, Fass J, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases[J]. Eur J Nucl Med, 1997, 24(6): 678-682.
[16] von Forstner C, Egberts JH, Ammerpohl O, et al. Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer[J]. J Nucl Med, 2008, 49(8): 1362-1370.
[1] XU Yujun, LIU Ming, HE Xiangmeng, LI Chengli. 1.0T open MRI-guided 125I seeds percutaneous implantation for advanced pancreatic cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(2): 21-25.
[2] GAO Ang, WANG Shijiang, FU Zheng, SUN Xindong, YU Jinming, MENG Xue. A feasibility study for boost target delineation using 18F-FDG PET/CT in local advanced non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(7): 73-77.
[3] LI Hongxia, DONG Lei, JIANG Jiong, WANG Xinyang. Effects of peptide YY on apoptosis of human pancreatic cancer cell line Miapaca-2 in vitro [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(12): 7-11.
[4] LI Mei-ying1, LI Ji-sheng1, YU Xue-jun1, SUN Li-mei1, WANG Ai-jun1, LIU Qi-ji2, WANG Xiu-wen1. Effects of bufalin on the proliferation and cell cycle of human pancreatic cancer CAPAN-2 cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(11): 37-41.
[5] ZHENG Hong-min. Expression of molealar imaging marker folate receptor alpha in pancreatic cancer and its significance [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(3): 83-85.
[6]

CUI Yazhou1, JIA Qing2, WANG Zhaopeng2, WANG Zhaoxia2,
ZHANG Yueying2, ZHANG Weidong2, HAN Jinxiang1

.

Polypeptide extract from scorpion venom inhibits
liver metastasis in pancreatic cancer

[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(03): 20-22.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!